If You Invested in Csl Ltd (CSLLY)

CSL Limited (CSLLY) is described as a global biotechnology and biopharma company with a dynamic portfolio of lifesaving medicines. According to company communications, its therapies include medicines that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. CSL states that it provides products to patients in more than 100 countries and operates through three main businesses: CSL Behring, CSL Seqirus, and CSL Vifor.

CSL reports that it has been active since 1916 and characterizes itself as driven by a promise to save lives using the latest technologies. Across its businesses, CSL emphasizes a combination of commercial strength, research and development focus, and operational capabilities that it uses to identify, develop and deliver new therapies for serious and rare conditions.

Business Structure and Therapeutic Focus

CSL Behring is presented as focusing on medicines for rare and serious diseases, including conditions such as haemophilia, hereditary angioedema (HAE), immune deficiencies and critical care indications. CSL highlights ANDEMBRY (garadacimab-gxii), a monoclonal antibody targeting factor XIIa, as part of its HAE franchise. ANDEMBRY is described as a once-monthly subcutaneous prophylactic treatment to prevent attacks of hereditary angioedema in eligible patients, with regulatory approvals reported in regions including the United States, the European Union, Australia, the United Kingdom, Japan, Switzerland and the United Arab Emirates.

CSL also points to HEMGENIX (etranacogene dezaparvovec-drlb), which it describes as a gene therapy for adults with hemophilia B. According to published Phase 3 HOPE-B trial data cited by CSL, HEMGENIX is administered as a one-time infusion and is intended to enable continuous production of factor IX, the deficient protein in hemophilia B. CSL reports that HEMGENIX has received regulatory approval in jurisdictions including the United States, Canada, the United Kingdom, Switzerland, Australia, Saudi Arabia, Taiwan, South Korea, Singapore and Hong Kong, and that it holds conditional marketing authorization from the European Commission for the European Union and European Economic Area.

CSL Seqirus is described as one of the largest influenza vaccine providers in the world and a contributor to influenza prevention globally. CSL Seqirus reports using egg, cell and adjuvant technologies to supply a portfolio of influenza vaccines in more than 20 countries. Real-world evidence studies referenced by CSL Seqirus indicate work on cell-based quadrivalent influenza vaccines and comparisons with standard egg-based vaccines.

CSL also highlights its collaboration with Arcturus Therapeutics on KOSTAIVE (ARCT-154), which is described as a self-amplifying mRNA COVID-19 vaccine. CSL states that KOSTAIVE is the first self-amplifying mRNA COVID-19 vaccine to receive marketing authorization from the European Commission and notes that it is marketed in Japan.

CSL Vifor is presented as focusing on iron deficiency and nephrology. CSL Vifor describes itself as specializing in strategic global partnering, in-licensing, and the development, manufacturing and marketing of pharmaceutical products for precision healthcare. It highlights its role in nephrology through products such as FILSPARI (sparsentan), a dual endothelin angiotensin receptor antagonist (DEARA) used in the treatment of IgA nephropathy (IgAN). CSL Vifor reports that FILSPARI has obtained approvals in the United States and Europe, and that it holds exclusive commercialization rights for FILSPARI in Europe, Australia, New Zealand and certain other territories.

Therapeutic Areas and Technologies

Across its businesses, CSL emphasizes several core therapeutic areas:

• Haemophilia and bleeding disorders: including hemophilia B, where HEMGENIX is positioned as a gene therapy that reduces the rate of abnormal bleeding by enabling continuous factor IX production.
• Immune deficiencies and immunology: CSL describes medicines for immune deficiencies and related conditions, as well as its long-standing involvement with hereditary angioedema through products such as ANDEMBRY.
• Influenza and vaccines: through CSL Seqirus, which reports work on egg-based and cell-based influenza vaccines and maintains manufacturing facilities in multiple regions.
• Iron deficiency and nephrology: through CSL Vifor, which focuses on therapies for iron deficiency and kidney-related diseases, including IgA nephropathy.

CSL also highlights its use of gene therapy and monoclonal antibody technologies. HEMGENIX is described as using an AAV5 viral vector to deliver genetic instructions for factor IX production, while ANDEMBRY is described as a recombinant monoclonal antibody that inhibits activated factor XII (FXIIa) at the start of the hereditary angioedema cascade. KOSTAIVE is presented as a self-amplifying mRNA vaccine that instructs cells to produce more mRNA and protein than conventional mRNA vaccines, with the aim of enhancing immune responses.

Geographic Reach and Operations

CSL reports that it is headquartered in Melbourne, Australia, and that it provides therapies to patients in more than 100 countries. It notes that its influenza vaccine business, CSL Seqirus, has production facilities in the United States, the United Kingdom and Australia, and that its products are supplied to markets in more than 20 countries. CSL Vifor is described as headquartered in St. Gallen, Switzerland, and as including the joint company Vifor Fresenius Medical Care Renal Pharma.

The company states that it employs tens of thousands of people globally, with figures in the provided materials indicating workforces in the tens of thousands across its operations. CSL emphasizes long-term involvement in specific disease areas, including more than four decades of work in hereditary angioedema.

Position in Biotechnology and Biopharma

According to its own descriptions, CSL positions itself as a global biotechnology company active in rare disease, vaccine and nephrology markets. It highlights a portfolio that spans plasma-derived and recombinant therapies, gene therapy, monoclonal antibodies, and vaccine platforms including egg-based, cell-based and self-amplifying mRNA technologies. The company repeatedly references its focus on serious and life-threatening conditions such as hemophilia B, hereditary angioedema, immune deficiencies, iron deficiency in specific clinical settings, nephrology indications including IgA nephropathy, and infectious diseases such as influenza and COVID-19.

CSL’s communications emphasize that its combination of commercial operations, research and development, and manufacturing capabilities is used to support the identification, development and delivery of new therapies. Its businesses—CSL Behring, CSL Seqirus and CSL Vifor—are presented as complementary parts of a broader biotechnology group focused on therapies for patients with significant unmet medical needs.